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2684sensitive marker of a depletional state (2). Although
inclusion in our cohort required loop diuretic use,
there were limited granular data on diuretic dosing
during hospitalization in our dataset. Therefore, we
were unable to draw any speciﬁc mechanistic con-
clusions regarding the contribution of diuretics to the
generation of hypochloremia.Justin L. Grodin, MD
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Is There an Ultimate Winner?We thank Drs. Agarwal and Argulian for their interest
in our review of coronary computed tomography
angiography (CCTA) for chest pain evaluation,
particularly in the context of serving as a “gate-
keeper” to unnecessary invasive coronary angiog-
raphy (ICA) (1,2). Based on the results of the recently
published PROMISE trial, which evaluated anatomic
versus functional imaging in a low- to intermediate-
risk cohort with suspected coronary artery disease
(CAD), Drs. Agarwal and Argulian assert stress echo-
cardiography as a “winner” in testing strategies
for the evaluation of patients with suspected CAD
(3). These claims, as argued by the letter writers,
are substantiated by the absence of ionizing radia-
tion, efﬁciency, and generally low cost of stress
echocardiography.
Although well intentioned, these assertions over-
simplify a complex interplay of an array of important
factors to consider, including the indication and
intent of testing, the patient population being tested,
the diagnostic performance of a test for any CAD andactionable CAD, the prognostic utility of imaging test
ﬁndings, and the inﬂuence of a diagnostic test ﬁnding
to encourage therapy in a fashion that improves
event-free survival. In our paper, we examined the
evidence supporting the use of CCTA as a “gate-
keeper” to unnecessary ICA in a patient population
that differs greatly from that enrolled in the PROMISE
trial, the study that Drs. Agarwal and Argulian cite.
Instead, we discussed the “anatomic-physiologic”
discordance that has been often observed for con-
ventional stress imaging wherein apparent ischemia
is present in the absence of high-grade anatomic CAD
at follow-up ICA. These ﬁndings do not necessarily
reﬂect a failure of stress imaging modalities to iden-
tify important cardiovascular ﬁndings but can repre-
sent alternative nonepicardial CAD processes that can
be elicited by stress imaging tests that inﬂuence
symptoms, diagnosis, and prognosis—a point fully
discussed in our paper.
Germane to this point, we also discussed the recent
iterations in CCTA wherein fractional ﬂow reserve
(FFRCT) can be noninvasively calculated at any point
in the coronary vascular bed from typically acquired
CCTA. This technology now allows for determination
of lesion-speciﬁc ischemia, a test ﬁnding eluded
by previous-generation imaging technologies. This
method for CAD evaluation is in its early stage
of clinical development, and we discussed the
emerging multicenter trials that will further evaluate
its efﬁcacy.
Finally, we highlighted the multitude of addi-
tional factors needed for consideration when evalu-
ating a patient with suspected CAD being considered
for ICA. Patient characteristics, test proﬁles, reason
for testing, clinical settings, test availability, local
expertise, payer coverage, functional capacity,
comorbidities, and a host of other important clinic-
economic considerations require consideration
before declaring any one imaging method an “ulti-
mate winner.” Drs. Agarwal and Argulian state that
the available literature favors stress echocardiogra-
phy as the winner thus far, but this assertion is un-
substantiated by scientiﬁc evidence. Indeed, the
totality of large-scale prospective multicenter studies
to date argues in favor of no single imaging modality
but rather has served to educate physicians as
to the beneﬁts and limitations of each testing
method, has emphasized that a binary dichotomy of
“this test versus that test” as an all-or-nothing
strategy is inappropriate, and has emphasized a
nuanced approach to judicious use of cardiac
imaging as the clinical standard, as reﬂected by
the contemporary American College of Cardiology/
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